Clinical Trial

Study of AHB-171 in Chronic Hepatitis B Participants

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)
Protocol Amendment History 2 changes
notable Trial sites expanded: 1 -> 10 locations 2026-07-22
critical Recruitment opened 2026-07-14
Trial Details
NCT Number NCT07630727
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions Hepatitis B, Chronic (CHB)
Enrollment 138 participants
Start Date 2026-06-24
Primary Completion 2029-03-31 (estimated)
Study Completion 2029-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-21